Select Media

Washington DC and Redwood City, Calif. – May 23, 2017 – Pulmonx, Inc. today announced the results of two multi-center, randomized clinical trials showing clinically meaningful improvements in lung function after treatment with the Zephyr® Endobronchial Valve (EBV) in emphysema patients without collateral ventilation. Six-month data from both the TRANSFORM and IMPACT trials, presented this Read More

Redwood City, Calif. – November 18, 2016 – The Global Initiative for Chronic Obstructive Lung Disease (GOLD) issued a substantial revision to its COPD management recommendations that now includes bronchoscopic lung volume reduction with endobronchial valves as a treatment option for patients with advanced emphysema and absence of collateral ventilation. The updated recommendations are based Read More